Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 13, 2014 - Issue 5
Submit an article Journal homepage
406
Views
10
CrossRef citations to date
0
Altmetric
Original Research

Acute mycophenolate overdose: case series and systematic literature analysis

Alessandro CeschiSwiss Toxicological Information Centre, Associated Institute of the University of Zurich, Freiestrasse 16, CH-8032 Zurich, Switzerland+41 44 634 1034; +41 44 252 8833; [email protected];University Hospital Zurich, Department of Clinical Pharmacology and Toxicology, Zurich, Switzerland
,
Claudia GregorianoUniversity and University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, Switzerland;University Clinic of Internal Medicine, Kantonsspital Baselland Liestal, Liestal, Switzerland
,
Christine Rauber-LüthySwiss Toxicological Information Centre, Associated Institute of the University of Zurich, Freiestrasse 16, CH-8032 Zurich, Switzerland+41 44 634 1034; +41 44 252 8833; [email protected]
,
Hugo KupferschmidtSwiss Toxicological Information Centre, Associated Institute of the University of Zurich, Freiestrasse 16, CH-8032 Zurich, Switzerland+41 44 634 1034; +41 44 252 8833; [email protected]
,
Nicholas R BannerHarefield Hospital, The Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, UK;National Heart and Lung Institute and Institute of Cardiovascular Medicine and Research, Imperial College, London, UK
,
Stephan KrähenbühlUniversity and University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, Switzerland
&
Anne B TaegtmeyerUniversity and University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, Switzerland
 show all
Pages 525-534 | Published online: 21 Mar 2014

Bibliography

  • Cellcept®. Product information. Roche Pharma (Schweiz) AG, Reihnach, Switzerland; 2013
  • Myfortic®. Product information. Novartis Pharma Schweiz AG, Risch, Switzerland; 2012
  • Abd Rahman AN, Tett SE, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease. Clin Pharmacokinet 2013;52:303-31
  • Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85-118
  • Kitchin JE, Pomeranz MK, Pak G, et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol 1997;37:445-9
  • Ensley RD, Bristow MR, Olsen SL, et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993;56:75-82
  • Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin Exp Rheumatol 1993;11(Suppl 8):S117-19
  • Budde K, Dürr M, Liefeldt L, et al. Enteric-coated mycophenolate sodium. Expert Opin Drug Saf 2010;9:981-94
  • Filler G, Foster J, Berard R, et al. Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. Transplant Proc 2004;36:1327-31
  • Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-55
  • Schutz E, Shipkova M, Armstrong VW, et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998;30:1185-7
  • Wieland E, Shipkova M, Schellhaas U, et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem 2000;33:107-13
  • Mycophenolate In: Poisindex® [Internet database]. Thomson Reuters (Healthcare), Inc., Greenwood Village, Colo; Updated periodically
  • Mycophenolate. In: ToxPoints® Summary [Internet database]. Thomson Reuters (Healthcare), Inc., Greenwood Village, Colo; Updated periodically
  • Persson HE, Sjoberg GK, Haines JA, et al. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol 1998;36:205-13
  • The Uppsala Monitoring Centre, Uppsala, Sweden. The use of the WHO-UMC system for standardised case causality assessment. Available from: who-umc.org/Graphics/24734.pdf [Last accessed 10 January 2014]
  • Ceschi A, Rauber-Luthy C, Kupferschmidt H, et al. Acute calcineurin inhibitor overdose: analysis of cases reported to a national poison center between 1995 and 2011. Am J Transpl 2013;13:786-95
  • Gregoriano C, Ceschi A, Rauber-Lüthy C, et al. Acute thiopurine overdose: analysis of reports to a national poison centre 1995 - 2013. PLoS One 2014;9:e86930
  • Myfortic®. Product information. Novartis Pharmaceuticals Corp., East Hanover, NJ, USA; 2013
  • Wu SW, Chang HR, Lai YR, Lian JD. Non-life-threatening leukopenia in a renal transplant recipient with acute overdose of mycophenolate mofetil. Transplant Proc 2008;40:3770-1
  • Bebarta VS, Heard K, Nadelson C. Lack of toxic effects following acute overdose of cellcept (mycophenolate mofetil). J Toxicol Clin Toxicol 2004;42:917-19
  • Filler G, Lathia A, LeBlanc C, Christians U. Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. Pediatr Nephrol 2006;21:1206-8
  • van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006;28:145-54
  • Seroquel. Product Information. AstraZeneca AG, Zug, Switzerland; 2012
  • Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 2008;36:D901-6
  • Jain A, Venkataramanan R, Kwong T, et al. Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. Liver Transpl 2007;13:791-6
  • Mauro LS, Nawarskas JJ, Maruo VF. Misadventures with activated charcoal and recommendations for safe use. Ann Pharmacother 1994;28:915-24
  • The PubChem Project. Available from: http://pubchem.ncbi.nlm.nih.gov/ [Last accessed 13 December 2013]
  • Howland MA. Activated charcoal. In: Nelson LS, Lewin NA, Howland MA, Hoffman RS, Goldfrank LR, Flomenbaum NE, editors, Goldfrank's toxicologic emergencies. 9th edition. McGraw-Hill Medical, New York, NY; 2010. p. 108-14
  • Hoffman RS. Understanding the limitations of retrospective analyses of poison center data. Clin Toxicol 2007;45:943-5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.